Rifafour e-275
Sponsors
Otsuka Frankfurt Research Institute GmbH, University of Cape Town, GlaxoSmithKline, Qurient Co., Ltd., TASK Applied Science
Conditions
Pulmonary TuberculosisTreatment-naïve, Sputum Smear-positive Patients With Drug-sensitive Pulmonary TBTuberculosis
Phase 1
Phase 2
Safety, Efficacy and Pharmacokinetics of OPC-67683 in Patients With Pulmonary Tuberculosis
CompletedNCT00401271
Start: 2006-11-30End: 2007-03-31Target: 54Updated: 2007-03-07
An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis
CompletedNCT03557281
Start: 2019-03-22End: 2021-12-14Updated: 2023-10-26
A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203)
CompletedNCT03563599
Start: 2018-07-23End: 2019-09-09Updated: 2019-09-10
Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis
CompletedNCT05382312
Start: 2022-07-26End: 2025-05-27Updated: 2025-10-07
Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis
CompletedNCT05896930
Start: 2017-11-09End: 2021-01-04Updated: 2023-06-09